Autotaxin as a marker for liver fibrosis in chronic HCV patients
Abd Razek, S., Osman, M., Mohammed, Z., El-zefzafy, W. (2021). Autotaxin as a marker for liver fibrosis in chronic HCV patients. EKB Journal Management System, 2(2), 142-148. doi: 10.21608/jram.2021.41308.1083
Safaa M Abd Razek; Magda Osman; Zakia A Mohammed; Wafaa El-zefzafy. "Autotaxin as a marker for liver fibrosis in chronic HCV patients". EKB Journal Management System, 2, 2, 2021, 142-148. doi: 10.21608/jram.2021.41308.1083
Abd Razek, S., Osman, M., Mohammed, Z., El-zefzafy, W. (2021). 'Autotaxin as a marker for liver fibrosis in chronic HCV patients', EKB Journal Management System, 2(2), pp. 142-148. doi: 10.21608/jram.2021.41308.1083
Abd Razek, S., Osman, M., Mohammed, Z., El-zefzafy, W. Autotaxin as a marker for liver fibrosis in chronic HCV patients. EKB Journal Management System, 2021; 2(2): 142-148. doi: 10.21608/jram.2021.41308.1083

Autotaxin as a marker for liver fibrosis in chronic HCV patients

Journal of Recent Advances in Medicine
Article 2, Volume 2, Issue 2, July 2021, Page 142-148  XML PDF (805.11 K)
Document Type: Original Article
DOI: 10.21608/jram.2021.41308.1083
View on SCiNiTO View on SCiNiTO
Authors
Safaa M Abd Razek email 1; Magda Osman2; Zakia A Mohammed2; Wafaa El-zefzafy3
1Clinical Pathology Department, Al-Mahalla Chest Hospital, Gharbia, Egypt.
2Clinical Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
3Hepatogastroenterology and Infectious Diseases Department, Faculty of Medicine for Girls, Cairo, Al-Azhar University, Egypt.
Abstract
ABSTRACT:
Background: Chronic hepatitis C is a major health problem. Noninvasive markers were developed to overcome liver biopsy complications. Autotaxin (ATX) is a lysophospholipase D enzyme that regulates lysophosphatidic acid (LPA) blood concentrations. Studies have suggested that the phenotypic changes during liver fibrosis may lead to changes in ATX level in the serum.
Objectives: to determine the serum Autotaxin levels and its correlation to the liver fibrosis and whether it can be used as a non-invasive diagnostic biomarker of fibrosis in Egyptian Chronic viral hepatitis C individuals.
Methodology: This study was conducted on 40 patients divided into 2 groups: Group I comprised of 20 patients with chronic viral hepatitis C patients in compensated stage and Group II comprised of 20 patients with chronic viral hepatitis C patients in decompensated stage together with 20 apparently healthy controls group. All patients were subjected to the following: complete history taking، complete clinical examination، routine lab investigations، abdominal ultrasound and measurement of serum ATX level detected by ELISA technique.
Results: 40 patients were enrolled. Serum ATX was significantly higher according to liver fibrosis worsen stage (p=0.002) ،ATX was significantly higher in decompensated chronic hepatitis C patients (CHC) compared to patients with compensated CHC and controls with mean values (646.7 ± 247.4) ، (615.3 ± 266) and (469.9 ± 62.3) ng/ml respectively (p=0.005).
Conclusion: Autotaxin was shown to be a potential serum marker for estimating the degree of fibrosis in patients with chronic HCV.
Keywords
Autotaxin; hepatitis C virus; liver fibrosis
Statistics
Article View: 213
PDF Download: 124